Hourglass dynamic image with organs and calcium chemical denomination letters Ca inside. Hourglass dynamic image with organs and calcium chemical denomination letters Ca inside. Hourglass dynamic image with organs and calcium chemical denomination letters Ca inside.

Management of chronic hypoparathyroidism may require

GOING BEYOND CALCIUM CONTROL

Hypoparathyroidism (HPT) is a rare endocrine disorder characterized by absent or inappropriately low levels of endogenous parathyroid hormone.1-3

Patients whose chronic HPT is inadequately controlled risk debilitating symptoms and disease complications impacting numerous organ systems.4

About Hypoparathyroidism

Hypoparathyroidism (HPT) is a rare endocrine disorder characterized by absent or inappropriately low levels of endogenous parathyroid hormone.1-3

Patients whose chronic HPT is inadequately controlled risk debilitating symptoms and disease complications impacting numerous organ systems.4

About Hypoparathyroidism

How much do you know?

Endogenous parathyroid hormone is a critical regulator of mineral homeostasis in several organ systems including…

BEGIN KNOWLEDGE ASSESSMENT

Varied symptom presentation

Patients with poorly controlled HPT may suffer from ongoing physical, emotional, and neuropsychiatric symptoms.5,6

Review HPT Symptoms
Doctor talking to patient about hypoparathyroidism symptoms.
Doctor looking at calcium levels in a microscope.

Going beyond calcium

Evaluating for adequate control in HPT patients on conventional therapy requires monitoring not only of serum calcium, but also of serum phosphate, calcium-phosphate product, and urinary calcium. Symptoms, quality of life, and comorbidities must also be observed.5

Identify inadequate control

For more information

Review HPT literature, downloadable resources, and support for healthcare professionals and patients.

BROWSE RESOURCES AND SUPPORT
Doctor looking at his tablet.

REFERENCES:

1. Mannstadt M, Bilezikian JP, Thakker RV, et al. Nat Rev Dis Primers. 2017;3:17055. doi:10.1038/nrdp.2017.55. 2. Shoback D. N Engl J Med. 2008;359(4):391-403. 3. Bilezikian JP, Khan A, Potts JT Jr, et al. J Bone Miner Res. 2011;26(10):2317-2337. 4. Mitchell DM, Regan S, Cooley MR, et al. J Clin Endocrinol Metab. 2012;97(12):4507-4514. 5. Brandi ML, Bilezikian JP, Shoback D, et al. J Clin Endocrinol Metab. 2016;101(6):2273-2283. 6. Shoback DM, Bilezikian JP, Costa AG, et al. J Clin Endocrinol Metab. 2016;101(6):2300-2312.